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Abstract: This paper is aimed at revising the
scientific literature about
mucopolysaccharidosis type III in order to
describe its main features. Firstly, the clinical
presentation as well as the different phenotypes
included in this syndrome are explained.
Secondly, biochemical exams used in the
specific diagnosis of this syndrome are
reviewed. Also, key points related to early
diagnosis, prenatal and genetics testings are
highlighted. The role of pediatricians and
primary care physicians as main actors in the
patients’ follow-up and the importance of other
specialists depending on the patients’ needs are
assessed. Finally, current treatment options and
experimental studies for new therapies are
described. The most relevant aspects of MPS III
are reviewed, facilitating the comprehension of
this disease and thus making the readers aware
of this challenge in medicine nowadays.
Resumen: El objetivo de este trabajo es revisar
la literatura científica acerca de la
mucopolisacaridosis tipo III con el fin de
describir sus características principales. Así, se
delimita el cuadro clínico y los fenotipos que se
consideran a la hora de estudiar este síndrome.
A continuación se analizan las pruebas
bioquímicas que se llevan a cabo para el
diagnóstico específico de esta patología.
Posteriormente se revisan puntos clave del
diagnóstico precoz y las pruebas actuales que
permiten realizar el diagnóstico prenatal y las
pruebas genéticas. Igualmente se establece el
papel del pediatra y del médico de atención
primaria como pilares principales en el
seguimiento del paciente así como la
importancia de otros especialistas en función de
las necesidades de este. Por último, se describen
las opciones de tratamiento existentes en el
momento actual y las terapias en vías
experimentales de mayor relevancia. De este
modo, evaluaremos los puntos más importantes
de la enfermedad, a fin de facilitar no solo la
comprensión de la misma, sino también
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procurando que el lector conozca el reto que





Palabras clave: Mucopolisacaridosis tipo III,
síndrome de Sanfilippo, glicosaminoglicanos,
retraso en el desarrollo.
Introduction
The mucopolysaccharidoses (MPS) are a group
of seven hereditary metabolic diseases character-
ized by a total or partial deficit of a lysosomal
enzyme (1), with subsequent accumulation of
molecules in the lysosomes that cells can not
digest. In the case of mucopolysaccharidoses,
the molecules accumulated are glycosaminogly-
cans (GAG), that are part of the connective tissue.
Given the ubiquitous presence of this tissue in
the body, these diseases have a multisystemic
impact.
MPS III or Sanfilippo syndrome is the most
frequent MPS (2). It is transmitted with a re-
cessive autosomic pattern and it is caused by a
defect in the enzymatic degradation of heparan
sulfate (1,3). There are four subtypes of MPS III
depending on the enzyme affected: A (heparan
N-sulfatase deficiency, the most severe form),
B (α–N-acetylglucosaminidase deficiency), C
(acetyl-CoA-α-glucosamide-acetyltransferase de-
ficiency) and D (N-acetyl-glucosamine-6-sulfatase
deficiency) (1).
The incidence of this disease is estimated
to be around 1 in every 70000 newborns, being
A and B subtypes more frequent than C and D
subtypes (3). Recently, a retrospective study was
carried out in Spain to analyze the natural his-
tory of MPS III in 55 patients with the disease.
The most common subtype was found to be MPS
IIIA which accounted for more than half of the
patients affected (4). Table 1 summarizes the
most relevant aspects of each subtype of MPS
III.
The present review highlights that, although
MPS III is a rare disease, the clinician should
always bear it in mind in the differential diagno-
sis of other less dramatic diseases, because its
initial diagnosis is essentially clinical (3). The
wide variety of signs and symptoms with which
the disease may appear early obliges a compre-
hensive analysis so that the clinician does not
ignore them.
Not only does the diagnostic algorythm mat-
ter; the follow-up is also extremely relevant be-
cause there are many stages of disease progres-
sion and the severity of the disease increases
as the stages advance. Correct identification
of these stages is required to apply the neces-
sary protective or paliative treatments. The lead-
ing role of the pediatrician and the primary care
physician in the multidisciplinary team is of ex-
treme relevance during the patients follow-up.
Several treatments have been tested with no cu-
rative outcomes. Although new therapies are
currently explored, they still belong to the exper-
imental field, and only paliative treatments are
available for the MPS III.
Synthesis of the review
Symptoms
Signs and symptoms of MPS III are very het-
erogeneous, and its diagnosis is very difficult
in comparison with the rest of MPS types, in
which bone abnormalities usually appear at an
early age, so they are diagnosed early. Besides,
there are no pathognomonic signs, so that the
absence of the signs described below does not al-
low to confirm the diagnosis. Common physical
signs (see Table 2) include: increased head cir-
cumference, thick eyebrows, tongue protrusion,
thick lips, increased amygdale volume, umbili-
cal hernias and hirsutism. Hepatosplenomegaly
and musculo-skeletal manifestations (scoliosis,
lumbar lordosis, kyphosis, hip dysplasia, carpal
tunnel syndrome, trigger finger) are not frequent
(5).
The clinical manifestations of MPS III patients
are essentially neurocognitive (6). Some studies
have reported structural and functional defects
of the blood-brain barrier which could explain
these alterations (7). Developmental delay is
usually the first sign that stands out. This de-
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lay often affects language and it can be the sole
sign noticed in the patient. For that reason it is
frequent to misdiagnose an idiopathic language
development instead of MPS III. Other patients
show a more general affectation of development,
so they are thought to suffer from the spectrum
of autism or idiopathic language development
(8).
After the developmental delay, the next clini-
cal manifestations often are disturbed behaviour
(see Table 2) and sleep disorders, which tend
to appear in advanced stages of the disease. Be-
sides, insomnia and nocturnal awakenings worsen
the disturbed behaviour. Recent studies have
shown that the blood concentration of melatonin
in these patients correlates with disruption of the
circadian rhythm. Therefore, treatments aimed
to the synchronization of the circadian rhythm
could be very useful (9).
Natural history
MPS III is a progressive disease with three differ-
ent stages that emerge after an apparently normal
development. Besides, depending on the degree
of affectation, two phenotypes with different nat-
ural histories are distinguished: mild and severe
,Since the severe phenotype is the most frequent,
its natural history will be described first, follow-
ing the three stages into which the disease is
divided.
In the first stage of the disease, which usu-
ally occurs between the first and the third year of
age, a slowing down or detention of the cognitive
development is observed. Motor development
usually evolves in a natural way during this stage.
Some characteristic physical signs as those de-
scribed above may appear.
The second stage starts approximately at the
third or fourth year and it is characterized by
progressive cognitive impairment, disturbed be-
haviour, impulsiveness, obstinacy, anxious and
autistic behaviour that get worse over time and
can be of extreme intensity.
The third stage usually appears during the
adolescence, when symptoms such as severe de-
mentia and impaired motor function emerge. Be-
havioural problems disappear gradually as the
patient loses motor control and experiments dif-
ficulty in swallowing and muscle spasticity. Fi-
nally, the patient falls into a vegetative state and
usually dies during the second or the third decade
of life (1).
Mild phenotype is characterized by a more
gradual progression of the disease and an in-
crease of longevity (10). The first phase starts
approximately at the age of four and it shows
a poor development and language delay. In the
mild phenotype, the second stage is the slowest,
compared with severe phenotype. Mild cogni-
tive impairment can remain stable during ado-
lescence or even adulthood before it progresses.
Behavioural problems, similar to those present in
severe phenotypes, also appear in patients suffer-
ing from mild phenotype, but they appear later
and are easier to deal with. The third stage and
death usually take place during the fourth and
sixth decade of life. However, there are cases re-
ported in the literature of survivors at the age of
seventy. Having into account that early diagnosis
in this group of population is especially difficult,
it is not strange that patients suffering from mild
phenotype are not diagnosed until adulthood.
Biochemical tests
Not all the laboratories are equipped with the
facilities required to carry out the analytical tests
of MPS III. The laboratory chosen shall be autho-
rized and have experience with this kind of tests.
As previously mentioned, MPS III is character-
ized by the impossibility to catabolize heparan-
sulfate. Therefore, not only this molecule ac-
cumulates in the tissues, but is also excreted in
excess through urine. The analysis of GAG in
urine could detect the excess of this molecule,
but it does not allow to distinguish between the
different subtypes of MPS.
The analysis of GAG in urine is the first step
in the biochemical diagnosis as it is unexpensive
and non-invasive. Traditionally, both semiquanti-
tative techniques (using cationic stainings, such
as Berry test, Ames spot, etc.) and quantita-
tive techniques (using spectrophotometric com-
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pounds, such as dimethylmethylene blue, alcian
blue, etc.) have been used. However, the former
have a relatively high rate of false positive and
negative results and have been set aside. In fact,
some authors consider that these are obsolete
tests (11). Therefore, quantitative techniques are
preferred whilst semiquantitative techniques are
not recommended as single screening test (see
Table 3).
To determine the specific MPS subtype, all
the samples with a high number of GAG will be
analyzed by qualitative techniques. Recently, a
technique based on liquid chromatography and
tandem mass spectrometry has been proved ef-
ficient to determine the subtype of MPS with
high specificity and sensitivity (12). Although
the analysis of GAG in urine is simple, some
factors must be considered. Firstly, patients with
MPS III have a lower number of GAG in urine
in comparison with other types of MPS. There
may be a high number of false negatives. There-
fore, a negative result in the urine analysis of
GAG does not rule out the diagnosis of MPS
III (3). Secondly, there may be false positives,
especially when electrophoresis is used. This
may happen if the urine sample is kept in a hep-
arinized test tube, because the heparin migrates
to the same position than heparan sulfate during
the electrophoresis. After the analysis of GAG
in urine, the enzyme activity tests are the gold
standard to confirm the diagnosis and determine
the subtype of MPS III. The enzyme activity can
be measured in cultures of skin fibroblasts, leu-
cocytes, plasma and serum and the four enzymes
from each subtype can be analyzed (13). Absent
or decreased activity in any of the enzymes in-
volved in the catabolism of heparan sulfate lets
the diagnosis of MPS III.
There is a great interest in determining the prog-
nostic value of the residual enzyme activity with
regards to the phenotype severity. However, it
has been proved that the level of residual enzyme
activity does not correlate with the disease phe-
notype (mild or severe) and shall not be used for
such purpose (14).
Early diagnosis
It is clear that mucopolysaccharidosis type III
means a diagnostic challenge, especially in early
stages and in the absence of family history of
the disease. The physician must examine the
whole patient and deduce a metabolic disease
from the set of signs and symptoms. During
the first phase, the patients typically experience
developmental and/or language delay, accompa-
nied by specific signs and symptoms (see table
2). The diagnostic examination process (starting
with the analysis of GAG in urine) is recom-
mended with the sole presence of developmental
delay and one of the specific physical features.
The aim of this test is to avoid mistakes in di-
agnosis and unnecessary treatments that are, as
mentioned above, quite frequent in this disease.
During the second phase, the developmen-
tal delay is accompanied by disturbed behaviour
and sleep disorders. The lack of response to
stimulating drugs for ADHD or to behavioural
therapy is a key clue to diagnose the disease at
this stage. Any of these neurocognitive signs,
alone or combined with typical physical features
of mucopolysaccharidosis type III, raise suspi-
cion of the disease and lead to the determination
of GAG in urine sample.
Prenatal diagnosis and genetic tests
Prenatal diagnosis can be performed in the chori-
onic villi and in the amniotic fluid. In the first
case, the test can be carried out since 10-12
weeks of pregnancy, while the amniotic fluid
test can be carried out since week 15-16. If the
genotype of the index case is available, prenatal
diagnosis can be carried out in the chorionic villi
without cultures because DNA can be extracted
directly. Then, the examination can be carried
out at the beginning of the gestation. If the muta-
tions from the index case are unknown, cultures
from chorionic villi and amniotic fluid will be
required.
Molecular genetic tests in the chorionic villi
or in amniotic fluid cells are available in some
centres for couples with family history of MPS
III as prenatal diagnosis test in subsequent gesta-
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tions. This is the only way to identify carriers of
the disease.
Several mutations have been reported regard-
ing all the 4 genes that cause the disease: 115 in
sulfamidase (MPS IIIA), 134 in N-acetylglucosa-
minidase (MPS IIIB), 54 in acetyl-CoA-glucosa-
mine-N-acetyltransferase (MPS IIIC) and 23 in
N-acetylglucosamine-6-sulfate sulfatase (MPS
IIID). Although several researchers have tried
to correlate the genotype with the fenotype of
each subtype of MPS III, no correlation has been
found yet.
Referral to specialists and follow-up
Early diagnosis is key for patients with MPS
III. If no screening test was carried out in the
newborn, the pediatricians are the main actors
involved as they see the children in early stages
of MPS III. Once the diagnosis is established,
the patient will be referred to the specialist on
metabolic diseases, but the role of the pedia-
trician is key in the follow-up of the patient.
During the follow-up, the patient will be re-
ferred to many other specialists, mainly cardiolo-
gists, neurologists, ophtalmologists, traumatolo-
gists, otolaryngologists, psychiatrists and pulmo-
nologists. Furthermore, additional support mea-
sures such as physiotherapy, occupational ther-
apy, speech therapy, audiology and behavioural
therapy, among others, could be required.
Treatment options
Since there are no curative therapies, several
treatments aimed to cure this disease are in de-
velopment. Clinical trials on humans are be-
ing carried out with intrathecal enzyme replace-
ment therapy (ERT) and substrate reduction ther-
apy (SRT). Besides, gene therapy and drug ther-
apy with chaperons are being studied in animal
models (15). The findings suggest that ideal re-
sults would be obtained when these therapies
are applied before an extense neurological dam-
age has occured. Hematopoietic stem cell trans-
plant with bone marrow cells has been carried
out. However, this treatment has not proved use-
ful in the prevention of neurocognitive impair-
ment even when carried out in early stages of
the disesase, so it is not considered as a feasible
treatment option. Despite this therapy failed to
prevent neurocognitive impairment, experiments
carried out on animals with umbilical cord blood
stem cells have shown promising results (16).
The intrathecal administration of ERT aimed
to reach the brain with an implantable device has
shown promising results in animal models with
MPS I and is currently being studied in patients
with MPS I, II and IIIA, in phase I/II clinical
trial (17).
Treatment of MPS IIIB with synthetic com-
pounds of soy isoflavone genisteins on mice has
shown potential, with reports showing complete
correction of the mice behaviour. These extracts
have been studied on humans in open trials, with
some improvements of the gastrointestinal symp-
toms, skin texture and rate of infections. How-
ever, the effects on the cognitive funcion and
global disability have been minimal (18).
Conclusions
Mucopolysaccharidosis type III is a hereditary
metabolic disease that has a diverse way of ap-
pearing, and a progressive clinical course, char-
acterized by a gradual neurocognitive decline,
disturbed behaviour or notably characteristic phys-
ical expression. Currently, no curative therapy
exists, but it is believed that an earlier establish-
ment of therapies that had not been proved to be
effective might become a remedial option. Thus,
early examination and diagnosis are crucial to op-
timize therapeutic outcomes. Pediatricians play
a key role in the identification of those patients
showing a set of symptoms that corresponds with
the profile of this metabolic disease. It is impor-
tant to underline the difficulty in this process and
the high frequency of false diagnosis. In fact,
due to the delicacy of its physical features, chil-
dren with mucopolysaccharidosis type III tend to
be misdiagnosed with a wide variety of diseases
such as language or idiopathic developmental
disorder, ADHD or autism. Physicians must be
careful then, and assess the whole patient con-
sidering the possibility of being a metabolic dis-
ease. The presence of delayed development or
language added to any other physical feature re-
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lated to the disease or disturbed behaviour must
lead to an early examination (See Figure 1). If in
doubt, the best procedure is diagnostic examina-
tion, because determination of GAG in urine is
cheap and non-invasive, although it must be con-
sidered that a negative result does not rule out the
disease. Enzyme activity must be tested in those
patients with positive GAG determination test in
urine and in those with a high probability of suf-
fering from this disease, being able to establish
the subtype of mucopolysaccharidosis through
this technique. Molecular genetics tests and pre-
natal diagnosis can be offered to the families of
patients suffering from mucopolysaccharidosis
type III as to identify carriers and ease informed
decisions by relatives. Once the diagnosis is
made, patients must be referred to a metabolic
disease specialist, but pediatricians and primary
care physicians still play a key role directing the
multidisciplinary teams.
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